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Although elevated cortisol levels may be found in diabetes, cortisol’s role in diabetes-associated cognitive
impairment is unclear. A recent study (Stranahan et al., 2008) shows that reducing glucocorticoid levels in
rodent diabetes models prevents cognitive deficits and enhances neurogenesis and synaptic plasticity.
The clinical relevance of these intriguing findings remains undetermined.Both type 1 and type 2 diabetes are asso-
ciated with cognitive impairments includ-
ingdeficits inprocessingspeed, executive
function, and declarative memory (Bies-
sels et al., 2008), functions associated
with the hippocampus and some other
brain regions. Unsurprisingly, diabetes is
associated with vascular dementia; unex-
pectedly, diabetes is also associated with
Alzheimer’s disease, whose incidence
is increased even inmerely borderline dia-
betics (Xu et al., 2007). Indeed, in healthy
(nondiabetic) elderly subjects,HbA1c (gly-
cosylated hemoglobin) levels within the
normal range correlate with cognitive
decrements (MacLullich et al., 2004). The
underlying mechanisms of the effects
of impaired glucose homeostasis on the
central nervous system (CNS) are unclear.
The possibilities include direct toxicity of
hyperglycemia (glycation of CNS macro-
molecules, increased oxidative stress/
reduced antioxidant capacity) or the ef-
fects of insulin deficiency on thebrain (hip-
pocampus expresses insulin receptors).
There are also a host of potential indirect
effects including deleterious CNS actions
of concomitant cardiometabolic disorders
(micro- and macrovascular disease, hy-
pertension, dyslipidemia), inflammation
and immune disturbances, and diabetic
neuropathies (Figure 1).
Elevated glucocorticoid levels (cortisol
in humans, corticosterone in rodents) are
also associated with aging-related cogni-
tive impairments and Alzheimer’s disease
and have been reported in some, but not
all, studies of diabetic patients (Bruehl
et al., 2007). Much evidence supports a
link between elevated glucocorticoids
andcognitivedysfunction. Exogenousglu-
cocorticoid administration and elevated286 Cell Metabolism 7, April 2008 ª2008 Elsendogenous glucocorticoids (Cushing’s
syndrome) are associated with cognitive
impairments in animals and humans
(MacLullich et al., 2005). Manipulations
that reduce glucocorticoid levels or their
action in target tissues attenuate cognitive
declinewith aging.Mechanistically, gluco-
corticoids exert direct effects upon hippo-
campal neurons, interfering with plastic
electrophysiological processes (such as
long-term potentiation) at the synapse
thought to play a role in learning andmem-
ory, attenuating dendritic complexity,
pruning synaptic density, and reducing
de novo neurogenesis. Glucocorticoids
also have indirect effects, sensitizing neu-
rons to metabolic and neurochemical
challenges such as glutamate excess, ox-
idative stress, and disrupted calcium ho-
meostasis (Herbert et al., 2006). Whether
glucocorticoids contribute to cognitive im-
pairment in diabetes is unknown.
Recently, Stranahan et al. (2008) used
young adult rat (streptozotocin; insulin-
deficient) and juvenile mouse (db/db; in-
sulin-resistant) models of type 1 and type
2 diabetes, respectively, to test the hy-
pothesis that elevated glucocorticoids
cause cognitive impairments in diabetes.
Cognitive function, dentate gyrus synaptic
plasticity, and neurogenesis were mea-
sured 30 days following adrenalectomy
and low-dose corticosterone replacement
or sham operation in diabetic rodents,
with additional comparison to nondiabetic
controls. Both diabetic models showed
marked cognitive deficits in two tests,
one of which (novel object recognition)
was a relatively stress-free procedure.
Furthermore, both models exhibited re-
duced hippocampal synaptic plasticity
and neurogenesis. The similarity of theevier Inc.cognitive defects observed in the two
models (insulin-resistant and insulin-defi-
cient) suggested that defective insulin
action in the CNS alone was an unlikely
cause.
Both diabetic models had markedly
elevated levels of corticosterone, at least
during the diurnal nadir (Stranahan et al.,
2008). These were lowered by more than
90% by the adrenalectomy and cortico-
sterone replacement approach. Crucially,
the cognitive and hippocampal plasticity
deficits ofdiabetic animalswere largely re-
versed by maintaining low corticosterone
levels, suggesting that elevated gluco-
corticoids were causal. Importantly, high-
dose corticosterone administration to
adrenalectomized type 2 diabetic db/db
mice also caused neural and cognitive
deficits, suggesting that adrenalectomy
or nonglucocorticoid adrenal factors
(catecholamines, mineralocorticoids) were
not likely to be implicated. Intriguingly,
maintaining low corticosterone levels by
adrenalectomy and low-dose replacement
did little to reduce hyperglycemia in dia-
betic rodents, suggesting that improved
glucose homeostasis was not responsible
for the improvements seen in cognition
and hippocampal cellular function.
Although these carefully performed
studies are intriguing and potentially im-
portant, some caveats must be raised.
The deleterious effects observed in these
diabeticmodels on the brain and cognitive
function might plausibly be attributable to
the massively increased corticosterone
levels (5-fold in the mouse and 8-fold in
the rat) independently of any effects of hy-
perglycemia. Such elevations in glucocor-
ticoid levels are probably much greater
than those seen in human diabetics of
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PreviewsFigure 1. Potential Routes of Central Nervous System Damage in Diabetes
There are multiple possible routes of CNS damage in type 1 and type 2 diabetes. This figure provides an overview of some of the major categories. The possible
role of elevated glucocorticoids in diabetes-induced cognitive impairment is yet to be established.comparable age (Lee et al., 1999). More-
over, a recent report suggests that in mid-
dle-aged type 2 diabetics, elevated corti-
sol levels may be confined to subjects
with at least mild diabetic complications
such as angiopathy, retinopathy, ne-
phropathy, and neuropathy (Chiodini
et al., 2007), suggesting a causative role
for ill health (stress) rather than diabetes
per se. Clearly, the diabetic rats and mice
used in the Stranahan et al. (2008) study
were ‘‘stressed’’ by their state, at least as
judged by the high levels of glucocorti-
coids achieved. Moreover, the animals
with adrenalectomy and low-dose re-
placement had considerably reduced cor-
ticosterone levels, less than half those of
the nondiabetic control animals. Whether
more physiological replacement has the
same benefits is likely but unproven;
a mildly glucocorticoid-insufficient (Addi-
sonian) state is hardly desirable.
Another issue raised by the Stranahan
et al. (2008) study is the exclusive focus
on effects on the hippocampus. Evidence
from some human neuroimaging and neu-
ropsychological studies indicates that
multiple brain regions and cognitive do-
mains may be affected in diabetes (Man-
schot et al., 2006; Brands et al., 2005),
though the hippocampusandothermedial
temporal structures appear to be particu-
larly vulnerable. Future work might exam-
ine the effects of elevated glucocorticoids
and diabetes upon a wider range of brain
systems and cognitive outcomes.In human diabetic populations, cogni-
tive decrements appear over a period of
years, and the myriad potential causal
factors (Figure 1) suggest that, particularly
in older patients, multiple pathogenic
pathways may be implicated (Biessels
et al., 2008). While some cognitive effects
of juvenile (largely type 1) diabetes might
stem from altered brain development,
the relevant target in adult (mostly type
2) diabetes is likely an aging and relatively
implastic brain. In this context, it is signif-
icant that Stranahan et al. (2008) utilized
juvenile animals and a comparatively
short exposure to glucocorticoid reduc-
tion, so it remains uncertain whether the
findings can be extrapolated to older
populations exposed to hyperglycemia
and elevated glucocorticoids for longer
periods. Indeed, as with diabetes, gluco-
corticoids may induce brain damage
by means of multiple routes operating
over different time frames (Herbert et al.,
2006).
So before diabetologists turn to their
phone books to look up their favorite
adrenal surgeon or scrutinize the pharma-
copoeia for adrenal synthesis inhibitors
and glucocorticoid receptor antagonists
(approaches which all have their own
pitfalls), it will be important to determine
whether studies of less severe but
chronic diabetes in appropriately aged
rodents with only modestly elevated cor-
ticosterone levels support these intriguing
findings.Cell MetabREFERENCES
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